New opportunities for anti-B-cell therapy in lupus nephritis. Resolution of the expert council

Lupus nephritis (LN) is one of the most common and clinically significant manifestations of systemic lupus erythematosus (SLE) and is associated with a high risk of disability. Delayed diagnosis of SLE in the Russian Federation and insufficient efficacy of standard treatment regimens necessitate the search for and implementation of new therapeutic approaches to improve patient outcomes. During the Expert Council meeting, current Russian and international clinical guidelines, data on the effectiveness of standard therapy, and the results of the international randomized phase III REGENCY clinical trial evaluating the efficacy and safety of obinutuzumab in patients with active LN were reviewed. The Expert Council resolution emphasizes that LN therapy requires a multidisciplinary approach. At the same time, the use of biologics, particularly obinutuzumab, opens new opportunities for achieving sustained remission, reducing glucocorticoid doses, and improving long-term prognosis in patients with highly active LN, including those with inadequate response to standard therapy.